GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Operating Income

Baudax Bio (Baudax Bio) Operating Income : $-35.02 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Operating Income?

Baudax Bio's Operating Income for the three months ended in Sep. 2023 was $-5.54 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-35.02 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Baudax Bio's Operating Income for the three months ended in Sep. 2023 was $-5.54 Mil. Baudax Bio's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Baudax Bio's Operating Margin % for the quarter that ended in Sep. 2023 was %.

Baudax Bio's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Baudax Bio's annualized ROC % for the quarter that ended in Sep. 2023 was -75.70%. Baudax Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -334.04%.


Baudax Bio Operating Income Historical Data

The historical data trend for Baudax Bio's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Operating Income Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Income
Get a 7-Day Free Trial -65.04 -47.07 -55.81 -52.38 -35.74

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.58 -20.76 -4.69 -4.03 -5.54

Baudax Bio Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baudax Bio  (OTCPK:BXRXQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Baudax Bio's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-22.16 * ( 1 - 0% )/( (31.598 + 26.946)/ 2 )
=-22.16/29.272
=-75.70 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Baudax Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-22.16/( ( (6.72 + max(-13.538, 0)) + (6.548 + max(-12.507, 0)) )/ 2 )
=-22.16/( ( 6.72 + 6.548 )/ 2 )
=-22.16/6.634
=-334.04 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.444) - (8.315 + 0 + 5.667)
=-13.538

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.975) - (11.35 + 0 + 2.132)
=-12.507

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Baudax Bio's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-5.54/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Baudax Bio Operating Income Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341

Baudax Bio (Baudax Bio) Headlines

From GuruFocus

Baudax Bio Announces Date of Reconvened Annual Meeting

By sperokesalga sperokesalga 06-06-2023

Baudax Bio Announces Closing of $4 Million Public Offering

By GlobeNewswire GlobeNewswire 05-01-2023

Baudax Bio Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Q4 2020 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Baudax Bio Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Q1 2022 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2021 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024